Tacrolimus
- Generic Name
- Tacrolimus
- Brand Names
- Advagraf, Astagraf, Envarsus, Modigraf, Prograf, Protopic, Tacforius
- Drug Type
- Small Molecule
- Chemical Formula
- C44H69NO12
- CAS Number
- 104987-11-3
- Unique Ingredient Identifier
- Y5L2157C4J
- Background
Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condi...
- Indication
Immediate-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, heart, or lung transplants, in combination with other immunosuppressants. Extended-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric ...
- Associated Conditions
- Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Oral Lichen Planus, Psoriasis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Atopic Dermatitis, Vitiligo, Moderate Atopic dermatitis
- Associated Therapies
- -
Conversion of Maintenance Prograf to Envarsus in Liver Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2022-12-19
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 40
- Registration Number
- NCT05655273
- Locations
- 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada
Uterus Transplantation to Treat Infertility
- Conditions
- Interventions
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 40
- Registration Number
- NCT05646992
- Locations
- 🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD
- Conditions
- Interventions
- First Posted Date
- 2022-11-18
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 92
- Registration Number
- NCT05621759
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis
- Conditions
- Interventions
- First Posted Date
- 2022-11-18
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 56
- Registration Number
- NCT05622318
- Locations
- 🇺🇸
Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationDrug: BusulfanDrug: CyclophosphamideProcedure: EchocardiographyDrug: FludarabineProcedure: Haploidentical Hematopoietic Cell TransplantationBiological: Lapine T-Lymphocyte Immune GlobulinProcedure: Matched Unrelated Donor Hematopoietic Cell TransplantationProcedure: Lumbar PunctureDrug: MelphalanDrug: MethotrexateProcedure: Multigated Acquisition ScanDrug: Mycophenolate MofetilProcedure: Myeloablative ConditioningOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationBiological: RituximabProcedure: T-Cell Depletion TherapyRadiation: Total-Body IrradiationDrug: TacrolimusDrug: Thiotepa
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 435
- Registration Number
- NCT05457556
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Phoenix Childrens Hospital, Phoenix, Arizona, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants
- Conditions
- Interventions
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT05364762
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
A Study to Evaluate Effect of IN-A001 on Pharmacokinetics of Tacrolimus in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 12
- Registration Number
- NCT05353010
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Tacrolimus Versus Hydrocortisone in Atopic Dermatitis
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 200
- Registration Number
- NCT05324618
- Locations
- 🇪🇬
Dermatology Clinic of National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt
Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2022-07-01
- Target Recruit Count
- 64
- Registration Number
- NCT05303727
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD Treatment
- Conditions
- Interventions
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 89
- Registration Number
- NCT05294666
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.